7ACC-2
7ACC-2 Basic information
- Product Name:
- 7ACC-2
- Synonyms:
-
- 7ACC 2
- 7ACC2
- 7ACC-2
- 7-[Benzyl(methyl)amino]-2-oxo-2H-chromene-3-carboxylic acid
- 7ACC 2; 7ACC-2; 7ACC 2; 7ACC-2
- 7-[benzyl(methyl)amino]-2-oxochromene-3-carboxylic acid
- 2H-1-Benzopyran-3-carboxylic acid, 7-[methyl(phenylmethyl)amino]-2-oxo-
- 7ACC2,MPC,MCT1,7ACC-2,Monocarboxylate Transporter,Inhibitor,lactate,pyruvate,Mitochondrial Metabolism,radiosensitizes,antitumor,mitochondrial,inhibit
- CAS:
- 1472624-85-3
- MF:
- C18H15NO4
- MW:
- 309.32
- EINECS:
- 604-604-1
- Product Categories:
-
- Inhibitors
- Mol File:
- 1472624-85-3.mol
7ACC-2 Chemical Properties
- Boiling point:
- 548.9±50.0 °C(Predicted)
- Density
- 1.368±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- solubility
- insoluble in EtOH; insoluble in H2O; ≥47.5 mg/mL in DMSO
- form
- Powder
- pka
- -98.37±0.20(Predicted)
- color
- Light yellow to yellow
7ACC-2 Usage And Synthesis
Uses
7ACC2 is a potent monocarboxylate transporter (MCT) inhibitor with an IC50 of 11 nM for inhibition of [14C]-lactate influx. 7ACC2 is also a potent inhibitor of mitochondrial pyruvate transport. 7ACC2 is an anticancer agent through inhibition of lactate flux[1][2].
Biological Activity
7acc2, a carboxycoumarin derivative, is a potent inhibitor of monocarboxylate transporter 1 (mct1), with an ic50 value of ~ 10 nm for lactate uptake in the human cervix carcinoma cell line siha. the family of mct is composed of 14 members, among which only four isoforms (i.e. mct1-4) have been documented to act as proton-linked transporters carrying short chain monocarboxylates such as lactate and pyruvate across cell membranes. in cancer cells, mct1 and mct4 are the most widely expressed, and mct1 shows a better affinity for l-lactate than mct4, enabling lactate entry into oxidative tumor cells. thus, mct1 blockade could serve as a potential therapeutic strategy to limit cancer progression. in addition, 7acc2 is also a potent inhibitor of mitochondrial pyruvate transport, which interferes with pyruvate import into mitochondria and ultimately prevents extracellular lactate uptake as efficiently as a mct1 inhibitor.1. draoui n, schicke o, fernandes a, et al. synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells. bioorganic & medicinal chemistry, 2013, 21(22): 7107-7117.2. corbet c, bastien e, draoui n, et al. interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects. nature communications, 2018, 9(1): 1208.
in vitro
7ACC-2 (compound 19; 72 hours) inhibits SiHa cells proliferation in lactate-containing medium with an EC50 of 0.22 μM. In SiHa cells, lactate uptake primarily depends on the high affinity MCT1 transporter.
It (compound 19) shows an excellent chemical stability in simulated gastric (SGF) and intestinal (SIF) fluids, a good apparent permeability coefficient (Papp) through Caco-2 monolayer and a high metabolic stability on mouse (MLM) and human liver microsomes ( HLM) as well as on human hepatocytes.
It is a potent inhibitor of mitochondrial pyruvate transport which consecutively blocks extracellular lactate uptake by promoting intracellular pyruvate accumulation.
p>
in vivo
7ACC-2 (3 mg/kg; intraperitoneal administration; daily; for 5 days or 10days) treatment significantly inhibits tumor growth in mice. It radiosensitizes tumor cells by reducing hypoxia in vivo.
The intraperitoneal administration of it (compound 19; 3 mg/kg) to mice leads to a C max of 1246 ng/ml (4 μM) in a very short time (T max =10 min) associated with a plasma half-life of 4.5 h.
| Animal Model: | 7-week-old female NMRI nude mice with radiotherapy administered |
| Dosage: | 3 mg/kg |
| Administration: | Intraperitoneal administration; daily; for 5 days or 10days |
| Result: | A significant increase in tumor growth delay was observed. |
target
| Target | Value |
| MCT1 () |